Oncology

Latest News

FDA Approved | Image credit: chrisdorney – stock.adobe.com

Teliso-V Approved to Treat Advanced NSCLC With High c-Met Protein Overexpression

By Hayden E. Klein

May 14th 2025

Telisotuzumab vedotin (Teliso-V) gained FDA approval as a targeted therapy for patients with advanced non–small cell lung cancer (NSCLC) with high c-Met overexpression, offering new hope.

While CTCs were identified regardless of disease stage, the current study identified large variations in the presence of CTCs between nonmetastatic and metastatic disease | Image Credit: Innovative Creation - stock.adobe.com

Flow Cytometry Can Reliably Identify CTC in Melanoma

By AJMC Contributor

May 14th 2025

Jack & Sheryl Morris Cancer Center | Image credit: RWJBarnabas Health

New Jersey’s First Freestanding Cancer Hospital Opens in New Brunswick

By Pearl Steinzor

May 14th 2025

At 3 months, hospitalizations among patients enrolled in RSM were 19% lower vs historical controls. | Image Credit: Nuttapong punna - stock.adobe.com

Remote Symptom Monitoring Linked to Reduced Hospitalization Risk for Patients With Cancer

By Rose McNulty

May 14th 2025

Offline data augmentation can significantly enhance deep learning techniques, improving classification performance compared to models trained solely on original clinician skin images. | Image Credit: Alexander - stock.adobe.com

Optimized Deep Learning Model Classifies Smartphone Images of Malignant Skin Lesions

By AJMC Contributor

May 12th 2025

Join this expert panel to discuss precision medicine in NSCLC, current immunotherapies, and more.

Watch the series now!

Join a panel of leaders as they discuss treatment for patients diagnosed with metastatic NSCLC without driver mutations

More News

October 5th 2017

Timing, Sequence Critical for Efficacy of Combination Immunotherapy Treatment

Surabhi Dangi-Garimella, PhD

A research study conducted in a mouse mammary cancer model has found that optimal timing, based on sequencing of immunotherapy agents, is important for treatment efficacy.

October 5th 2017

Survey Quantifies Precision Medicine Awareness Among Health System Leaders

Surabhi Dangi-Garimella, PhD

A new survey conducted by The Health Management Academy has identified a rapid investment by leading healthcare systems in precision medicine programs, with significant expectations of the impact of real-world outcomes on physician decision making.

October 4th 2017

Fas Biomarker Predicts Response to Second-Line Therapy for Advanced Soft Tissue Sarcoma

Aaron Lyss on Challenges When Transitioning to Value-Based Payments

October 4th 2017

Aaron Lyss on Challenges When Transitioning to Value-Based Payments

There are 2 categories of challenges facing oncology practices as they transition to value-based payment models, said Aaron Lyss, director of value-based care for Tennessee Oncology.

October 4th 2017

Drop in Breast Cancer Death Rate Saved More Than 322,000 Lives From 1989 to 2015

Laura Joszt, MA

While death rates from breast cancer declined 39% from 1989 to 2015, there are clear racial differences with black women having higher breast cancer death rates than white women, according to a new report from the American Cancer Society.

October 3rd 2017

ASCO, Friends of Cancer Research Call for More Inclusive Cancer Clinical Trials

Christina Mattina

Clinical trials researching cancer therapies should be more inclusive of a broader range of patients, according to the American Society of Clinical Oncology (ASCO) and Friends of Cancer Research.

October 2nd 2017

Updates to Treatment Options During Breast Cancer Awareness Month

Surabhi Dangi-Garimella, PhD

October is breast cancer awareness month, and as September ended, a new treatment received the FDA’s approval for advanced breast cancer and another was granted priority review for the adjuvant treatment of early breast cancer.

Dan Todd Highlights Policy Changes Community Oncologists Should Look Out For

October 2nd 2017

Dan Todd Highlights Policy Changes Community Oncologists Should Look Out For

Drug pricing is one area where there may be potential future policy changes that impact community oncologists, said Dan Todd, JD, principal at Todd Strategy.

October 1st 2017

Study Finds Outreach Interventions Effective for CRC Screenings

Alison Rodriguez

Outreach interventions, including mail outreach invitations, may be effective in increasing the proportion of completed colorectal cancer screening, according to research.

Podcast: This Week in Managed Care - Latest ACA Repeal Fails, and Other Health News

September 30th 2017

Podcast: This Week in Managed Care - Latest ACA Repeal Fails, and Other Health News

Every week, The American Journal of Managed CareÂ® recaps the top managed care news of the week, and you can now listen to it on our podcast, Managed Care Cast.

September 29th 2017

5 Takeaways for Payers and Providers From the NCCN Meeting on Quality Metrics

Surabhi Dangi-Garimella, PhD

Key lessons learnt at the National Comprehensive Cancer Network's policy meeting: Redefining Quality Measurement in Oncology.

September 29th 2017

Navigating the Quality Landscape in Oncology: Pitfalls and Lessons Learned

Surabhi Dangi-Garimella, PhD

Ensuring access to appropriate data and then using the information to improve healthcare outcomes remains an ongoing challenge-this was the conclusion drawn by panelists participating at the National Comprehensive Cancer Network’s Oncology Policy Summit on Redefining Quality Measurement in Oncology.

This Week in Managed Care: September 29, 2017

September 29th 2017

This Week in Managed Care: September 29, 2017

This week, the top managed care stories included the end of the latest attempt to repeal the Affordable Care Act; a call to better include the patient's voice in cancer quality metrics; and an argument for caution regarding the newly approved CAR T-cell therapy, Kymriah.

September 29th 2017

Report Finds Hospitals Costlier for Cancer Care Than Community Practices

Christina Mattina

Not only do patients with cancer incur higher costs when treated in the hospital outpatient setting compared with community oncology practices, they also have higher rates of emergency department visits, according to a recent study.

September 28th 2017

Researchers Categorize Incurable Childhood Brain Tumors as Separate Cancer Types

Christina Mattina

After examining over 1000 cases of high-grade gliomas in children and young adults, researchers have split these rare brain tumors into at least 10 different subtypes, which could help clinicians choose and deliver more effective treatments.

Dr Amy Abernethy Outlines How Technology Is Improving Clinical Trial Participation

September 28th 2017

Dr Amy Abernethy Outlines How Technology Is Improving Clinical Trial Participation

As clinical trials get more complex and fewer patients are available to participate in any particular trial, technology is going to be critical for improving patient access to trials and making the whole process of being on a trial easier for patients and physicians, explained Amy Abernethy, MD, PhD, the chief medical officer, chief scientific officer, and senior vice president of oncology at Flatiron Health.

September 28th 2017

Early Imaging Can Identify Positive Immunotherapy Responders in Advanced Melanoma

Surabhi Dangi-Garimella, PhD

Combining positron emission tomography and computed tomography early in the treatment plan for patients diagnosed with advanced melanoma can help identify the potential benefit of a specific immunotherapy and avoid the risk of non-beneficial intervention.

September 27th 2017

Research Finds Cancer Survivorship Care Lacking in Advanced Primary Care Practices

Christina Mattina

A new case study of 12 advanced primary care practices found that none provided comprehensive cancer survivorship care, which the authors attributed to insufficient information systems and difficulties identifying survivors.

September 27th 2017

Report: Immune Checkpoint Proteins Are the Focus of Cancer Immunotherapy Development

Alison Rodriguez

Advancements in the cancer immunotherapy pipeline are leading to the production of immune checkpoint inhibitors, and a recent report from Global Business Intelligence (GBI) Research titled “Cancer Immunotherapies-First-in-Class Pipeline Dominated by Immunomodulators and PD-1 Like Targets” took a look at the pipeline.

Aaron Lyss: Nuances of Oncology Make Creating Value-Based Payment Models a Challenge

September 26th 2017

Aaron Lyss: Nuances of Oncology Make Creating Value-Based Payment Models a Challenge

While the healthcare industry moves more toward value-based payment models, oncology practices are at a disadvantage because few payers truly understand the nuances of cancer care to design good oncology payment models, explained Aaron Lyss, director of value-based care for Tennessee Oncology.

September 26th 2017

Title X Health Centers Reducing Cervical Cancer Screening in Accordance With Guidelines

Christina Mattina

Among women treated at health centers receiving federal funding under Title X, the proportion receiving cervical cancer screening tests declined significantly from 2005 to 2015, according to new research.

September 26th 2017

Lending the Patient Voice to Oncology Quality Measurement

Surabhi Dangi-Garimella, PhD

At the National Comprehensive Cancer Network's Oncology Policy Summit, a physician administrator from the MD Anderson Cancer Center discussed weaving the patient focus into outcomes measurements.

September 25th 2017

JAMA Commentary Urges Realistic View of New CAR T-Cell Cancer Therapy

Christina Mattina

While the FDA’s approval of the immunotherapy tisagenlecleucel represents a landmark in the oncology field, the treatment is far from being a cure and should be viewed in context of its $475,000 price tag, a group of oncologists wrote in a commentary published in JAMA.

September 25th 2017

New Advance Value Framework Offered as a Decision-Support Tool for Reimbursement

Surabhi Dangi-Garimella, PhD

Researchers at the London School of Economics and Political Science have developed a multiple criteria decision analysis model, The Advance Value Framework, that payers can utilize for evaluating new medicines that come to the market.

Nat Turner on Flatiron Health's Emphasis on Community Oncologists

September 24th 2017

Nat Turner on Flatiron Health's Emphasis on Community Oncologists

Flatiron Health focuses on helping community oncologists because they still care for the majority of patients with cancer and make it possible for patients to get care without traveling long distances, explained Nat Turner, co-founder and CEO of Flatiron Health.

September 23rd 2017

Immune Adverse Events From Nivolumab Predict Better Survival With NSCLC

Christina Mattina

When immune-related adverse events arise from nivolumab, it may indicate that the therapy is having greater efficacy against non—small-cell lung cancer (NSCLC), as a new study demonstrates a link between these events and improved survival outcomes.

September 21st 2017

Link Found Between Childhood-Onset IBD, Higher Cancer Risk

Christina Mattina

Childhood-onset inflammatory bowel disease (IBD) is known to cause painful gastrointestinal symptoms, but a new study of Swedish patients finds that it is also associated with an increased risk of cancer.

September 20th 2017

Review Outlines Recent Advances in Radiotherapy for Cancer

Christina Mattina

A new review article published in the New England Journal of Medicine explores the recent developments in radiotherapy that have improved survival and quality of life for patients with cancer.

September 20th 2017

Physicians Develop Guidelines to Manage CAR T-Cell Toxicity

Surabhi Dangi-Garimella, PhD

Physicians across different institutes who have been involved in clinical trials of chimeric antigen receptor (CAR) T cells in B-cell lymphomas have developed a guideline for monitoring and managing the symptoms associated with this treatment.

September 19th 2017

Encouraging Physical Activity After Cancer Requires Oncologist Involvement, Researchers Say

Christina Mattina

A new commentary suggests that interventions to promote physical activity in survivors of cancer should be delivered at home and guided by oncologists.

...

64 65 66 67 68 69 70 71 72

...

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences^® and AJMC®.
All rights reserved.

Editorial Boards

Do Not Sell My Information

Terms & Conditions